Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 13/20 | 0.36 |
| ▸ | THRB | P10828 | 13/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3156744 | 0.94 | THRA (0.36) | THRATHRBHSP90AA1HSP90AB1 | |
| SCHEMBL282260 | 0.78 | THRA (0.42) | THRATHRB | |
| SCHEMBL282259 | 0.78 | THRA (0.42) | THRATHRB | |
| SCHEMBL285533 | 0.73 | THRA (0.65) | THRATHRB | |
| SCHEMBL283090 | 0.73 | LMNA (0.39) | THRATHRBHSP90AA1HSP90AB1 | |
| SCHEMBL13381730 | 0.72 | THRA (0.55) | THRATHRB | |
| SCHEMBL22088831 | 0.69 | THRA (0.52) | THRATHRB | |
| SCHEMBL4322937 | 0.66 | GABRA1 (0.46) | THRATHRBHSP90AA1HSP90AB1 | |
| SCHEMBL30583122 | 0.66 | GABRA1 (0.46) | THRATHRBHSP90AA1HSP90AB1 | |
| SCHEMBL5406088 | 0.63 | THRB (0.51) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-7514419-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | PYGL, THRA, THOP1 | THRA 2/4885THRB 6/4885HSP90AA1 2138/4885 |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | PYGL, THRA, THOP1 | THRA 2/4885THRB 6/4885HSP90AA1 2138/4885 |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | THRA 14/4885THRB 41/4885HSP90AA1 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.